|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||8.15 / 24.45|
These names are moving up or down in a big way ahead of releasing drug-trial results.
American Society of Clinical Oncology will see presentations from dozens of companies.
After a strong week for the biotech sector, these names have potential catalysts to move shares.
Data and industry conferences will likely be catalysts for shares in the space.
Your questions are answered in our latest addition of the biotech mailbag.
Investors in Dynavax Technologies Corp saw new options become available this week, for the May 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DVAX options chain for the new May 18th contracts and identified one put and one call contract of particular interest.
Jim Cramer spotlights Twilio, Apache, Tellurian, Atara Biotherapeutics, Amarin, Dynavax Technologies
Jim Cramer says this is a market that triumphs over the gloom by simply taking stock of the good and running with it. He's got your game plan for next week.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Dynavax Technologies Corp , where a total volume of 8,938 contracts has been traded thus far today, a contract volume which is representative of approximately 893,800 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 76.2% of DVAX's average daily trading volume over the past month, of 1.2 million shares.
Dr. Plotkin Will Continue as Scientific Advisor
Investors in Dynavax Technologies Corp saw new options become available this week, for the October 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
HEPLISAV-B is the First and Only Two-Dose Vaccine in the U.S. for Hepatitis B Prevention in Adults
Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.
A roundup of biotech names with actions pending at the FDA in coming weeks.
HEPLISAV-B is the First and Only Two-Dose Vaccine in U.S. for Hepatitis B Prevention in Adults
Readers have asked about Acadia Pharmaceuticals and Dynavax Technologies, so we answer.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.